External Factor Evaluation Matrix: Opportunities Weight Rating Weighted Average

WEIGHTED
OPPORTUNITIES WEIGHT RATING

AVERAGE
Export increased in global pandemic 0.11 3 0.33
Demand for medicines globally and locally in Covid’19 0.16 4 0.64
Market growth and sales increased due to pandemic 0.10 4 0.4
Participation in tenders 0.08 3 0.24
Global trade easier for Pharma products in Covid’19 0.07 3 0.21
WEIGHTED
THREATS WEIGHT RATING
AVERAGE
Issues in importing API (Active Pharmaceutical Ingredient) 0.06 2 0.12

due to Covid-19
Rise in inflation leading to low revenue 0.09 2 0.18
Price monitoring and control by Drug Regulatory Authority of 0.1 2 0.2

Pakistan (DRAP)
Rising number of competitors 0.16 2 0.32
Adaptive towards new technology 0.07 2 0,14
TOTAL 1.00 2.78
EXTERNAL FACTOR EVALUATION MATRIX
QUANTITATIVE STRATEGIC PLANNING MATRIX – QSPM

KEY FACTOR WEIGHT AS TAS AS TAS AS TAS AS TAS
STRENGTHS
Economic products with good quality
and strong corporate governance
Sturdy management with resourceful
knowledge
Certified and governed with Pharma
Inspection Co-operation Scheme
(PIC/S)
Product export in multiple countries
(approx. 15)
Superior research and fond of
innovation
WEAKNESSES
Field force not fully aware of
products
High turnover rate among employees
Production volume is low
Major import (above 90%) of Active
Pharmaceutical Ingredient (API)
Not well educated and low product
knowledge within pharmacists
SUM WEIGHT
OPPORTUNITIES
Demand for medicines globally and
locally in Covid’19
Global trade easier for Pharma
products in Covid’19
Participation in tenders
Export increased in global pandemic
Market growth and sales increased
due to pandemic
THREATS
Issues in importing API (Active
Pharmaceutical Ingredient) due to
Covid-19
Rise in inflation leading to low
revenue
Adaptive towards new technology
Price monitoring and control by Drug
Regulatory Authority of Pakistan
(DRAP)
Rising number of competitors
SUM WEIGHT
COMPETITIVE PROFILE MATRIX - CPM
COMPANY PROFILE OF AGP

As an independent pharmaceutical manufacturing company, AGP started commercial
operations in Karachi, Pakistan, in 1989. AGP has gradually expanded by manufacturing and
selling products under licensing agreements with several well-known foreign firms, as well as by
manufacturing and marketing its own brands.
COMPANY PROFILE OF SANOFI AVENTIS

Sanofi is committed to assisting people in overcoming health problems. We are a
biopharmaceutical corporation specializing in human health. Sanofi is translating scientific
breakthroughs into global healthcare solutions. We use vaccines to prevent infections, and we
support the few who suffer from rare diseases and the millions who live with long-term chronic
conditions.
COMPANY PROFILE OF HIGH NOON LABORATORIES

Highnoon Laboratories Limited was established in March 1984 as a Private Limited Company. It
became a public limited company in 1995, and its shares are traded on all Pakistani stock
exchanges. Highnoon is constantly re-aligning its portfolio in order to capitalize on
opportunities. Simultaneously, the Company is modernizing its facility by investing in new
equipment and technologies to improve its manufacturing capabilities. Since then, High noon
has continued to innovate by launching cutting-edge innovations and setting new trends.
COMPANY PROFILE OF FEROZSONS LABORATORIES

Ferozsons Laboratories Limited is a Pakistan Stock Exchange-listed public limited company that
was established in 1960. Ferozsons has market-leading brands in gastroenterology, hematology,
cardiology, and oncology, as well as a growing presence in endocrinology and maternal and
child health in the diabetes market. Ferozsons is one of Pakistan's leading firms, with exclusive
distribution, selling, and co-manufacturing deals with a variety of foreign partners.
CPM – COMPETITIVE AGP Sanofi Searle High noon

PROFILE MATRIX Pharmaceutica Aventis Pharmaceutica Laboratories
ls ls
Critical Success Factor Weigh Ratin Weighted Ratin Weighte Rating Weighted Rating Weighte
t g Score g d Score Score d Score
 Each drug product's
clinical trial data is
available.
 Drug Products in a Variety

of Dosage Forms
 Capacity of production
 Technological
Advancement
 Stock availability
 Product affordability
 Product Promotion &

Brand Responsiveness
 Extensive Product
Portfolio
 Corporate Social
Responsibility Initiatives
 Strong emphasis on the

exports
TOTAL 1

External Factor Evaluation Matrix: Opportunities Weight Rating Weighted Average

Uploaded by

Copyright:

Available Formats

External Factor Evaluation Matrix: Opportunities Weight Rating Weighted Average

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

External Factor Evaluation Matrix: Opportunities Weight Rating Weighted Average

Uploaded by

Copyright:

Available Formats

WEIGHTED

OPPORTUNITIES WEIGHT RATING

Export increased in global pandemic 0.11 3 0.33

Demand for medicines globally and locally in Covid’19 0.16 4 0.64

Market growth and sales increased due to pandemic 0.10 4 0.4

Participation in tenders 0.08 3 0.24

Global trade easier for Pharma products in Covid’19 0.07 3 0.21

Issues in importing API (Active Pharmaceutical Ingredient) 0.06 2 0.12

Price monitoring and control by Drug Regulatory Authority of 0.1 2 0.2

Adaptive towards new technology 0.07 2 0,14

TOTAL 1.00 2.78

EXTERNAL FACTOR EVALUATION MATRIX

QUANTITATIVE STRATEGIC PLANNING MATRIX – QSPM

COMPETITIVE PROFILE MATRIX - CPM

COMPANY PROFILE OF AGP

COMPANY PROFILE OF SANOFI AVENTIS

COMPANY PROFILE OF HIGH NOON LABORATORIES

COMPANY PROFILE OF FEROZSONS LABORATORIES

CPM – COMPETITIVE AGP Sanofi Searle High noon

 Drug Products in a Variety

 Product Promotion &

 Strong emphasis on the

You might also like